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Colorectal  carcinoma  is  a signiﬁcant  source  of major  morbidity  and  mortality.  Sonic  hedge-
hog (Shh)  is  expressed  in normal  gastrointestinal  tract  mucosa  and  in  many  malignancies.
The  purpose  of the  present  study  is to investigate  the relationship  between  Shh  immuno-
expression  in CRC  and  clinicopathological  characteristics.  Parafﬁn  blocks  of  155  primary
CRCs  and  37  nodal  metastases  were  retrieved  and  tissue  microarrays  were  constructed.
Immunohistochemistry  was  performed  using  anti-Shh  antibody.  Immunostaining  was
scored  and  results  were  analysed  in relation  to the  clinicopathological  parameters.  Shh
was overexpressed  in  primary  CRC  (p = 0.02)  and  in  nodal  metastasis  (p  = 0.004).  There  was
no difference  between  Shh  immunoexpression  in  primary  CRC  and  in  nodal  metastasis
(p  =  0.941).  High  Shh  immunoexpression  was  associated  with  well  differentiated  tumours
(p  =  0.004).  However,  there  was  no association  with  other  clinicopathological  parameters.
Shh  overexpression  was  not  associated  disease  free  survival  (log-rank  =  0.079,  p =  0.778).
Shh is  overexpressed  in  well  differentiated  CRC.  However,  Shh  is  not  associated  with  other
clinicopathological  and  prognostic  factors.  Loss  of Shh  may  be  associated  with  prolifera-
tion  and  loss  of  differentiation  in CRC.  Further  molecular  studies  are  required  to address
the  potential  importance  of Shh  signalling  in  CRC  and  to test  Shh  inhibitors  and  activators
as  potential  therapeutic  targets  in  CRC.
©  2015  Saudi  Society  of  Microscopes.  Published  by  Elsevier  Ltd.  All  rights  reserved.. IntroductionColorectal carcinoma (CRC) incidence and mortality
ates remain one of the highest among other types of cancer
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213-879X/© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All riworldwide [1]. Nodal metastasis and tumour stage remain
the most important prognostic factors that the treatment
plan is decided upon [2]. The pathogenesis of CRC involves a
sequential process of genetic and molecular alterations that
enhance cellular proliferation and suppress apoptosis [1,3].
It is essential to analyse these steps and correlate them with
embryonic basis in order to identify other prognostic fac-
tors and modulate new targeted molecular interventions.
Cellular differentiation and proliferation during
embryogenesis is regulated through the hedgehog (Hh)
ghts reserved.
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Table 1
Clinicopathological parameters of cases (n = 155).
Parameter Number (%)
Sex Male 78 (50.3%)
Female 77 (49.7%)
Grade Well differentiated 36 (23.2%)
Moderately differentiated 98 (63.2%)
Poorly differentiated 21 (13.5%)
Age <60 years 88 (56.8%)
≥60 years 67 (43.2%)
Tumour location Right colon 41 (26.5%)
Left colon 98 (63.2%)
Rectum 16 (10.3%)
Tumour size <5 cm 68 (43.9%)
≥5 cm 87 (56.1%)
Primary tumour T1 3 (1.9%)
T2 22 (14.2%)
T3 116 (74.8%)
T4 14 (9%)
Nodal metastasis Negative 80 (51.6%)
Positive 68 (43.9%)
Cannot be assessed 7 (4.5%)
Distant metastasis Negative 111 (71.6%)
Positive 44 (28.4%)
Lymphovascular
invasion
Negative 132 (85.2%)
Positive 23 (14.8%)
Margin status Free 149 (96.1%)
Involved 6 (3.9%)
Disease relapse Negative 98 (63.2%)
Positive 57 (36.8%)
Survival Alive 94 (60.6%)
Dead 26 (16.8%)
Not available 35 (22.6%)
T1: tumour invades submucosa; T2: tumour invades muscularis propria;
T3: tumour invades through the muscularis propria into the subserosa or
into non-peritonealised pericolic or perirectal tissues; T4: tumour directly
invades other organs or structures, and/or perforates visceral peritoneum.
signalling pathway [2]. Three members of the mammalian
hedgehog were identiﬁed, Desert hedgehog (Dhh), Indian
hedgehog (Ihh), and Sonic hedgehog (Shh) [4]. Shh expres-
sion was reported in normal gastrointestinal tract [2,5].
Continuous Shh signalling activity had been documented
in multiple cancers, such as basal cell carcinoma, breast
cancer, gastric cancer, pancreatic cancer, and CRC [5,6]. The
activity of Shh signalling results in activation and nuclear
translocation of the Gli family of transcription factors
through multiple intracellular events. These transcription
factors control the transcription of hedgehog target genes
[7,8].
The aim of the present study is identify the signiﬁcance
of Shh immunoexpression in CRC in relation to the clinico-
pathological entities and patient outcome.
2. Materials and methods
2.1. Patients
The study included parafﬁn wax blocks of primary
tumour from 155 patients with CRC and correspond-
ing 37 nodal metastases. Blocks were retrieved from the
archives of the Department of Pathology at King Abdulaziz
University, Jeddah, Saudi Arabia. Clinicopathological char-
acteristics of patients are listed in Table 1. The study was
approved by the Research Committee of the Biomedical
Ethics Unit, Faculty of Medicine, King Abdulaziz University.d Ultrastructure 3 (2015) 169–174
2.2. Tissue microarray
Tissue microarrays (TMA) were designed and con-
structed as previously described [9]. Haematoxylin and
eosin-stained sections of primary tumours and nodal
metastasis were reviewed by an experienced pathologist
(WG). Areas of interest were chosen from the original
blocks and were marked on the slides. Necrotic areas,
autolytic areas and areas containing predominantly the
stromal tissue were avoided. Primary CRC and nodal
metastasis parafﬁn-embedded blocks were retrieved and
examined for validity to perform TMA. Two tissue cores
each 1.5 mm in diameter were punched from each donor
block in an automated TMA  instrument (TMA Master 1.14
SP3 from 3D Histech Ltd., Budapest, Hungary) and inserted
into a recipient parafﬁn block. Placental tissue was  used for
orientation. Slides were cut from TMA  block and stained
with haematoxylin and eosin for initial morphological
assessment of accuracy of construction.
2.3. Immunohistochemistry
TMA  blocks were cut at 4 m,  and mounted on
positive-charged slides (Leica Microsystems Plus Slides).
Sections were deparafﬁnised in xylene and rehydrated in
an automated immunostainer (BenchMark XT, Ventana®
Medical systems Inc., Tucson, AZ, USA). Pre-treatment was
done using CC1 (prediluted cell conditioning solution) for
60 min. Anti-human rabbit anti-Shh polyclonal antibody
(SpringTM Bioscience; Cat # E17920) was  incubated at 37 ◦C
for 20 min. Ventana® I-view DAB detection kit was used
according to kit manufacturer instructions. Subsequently,
slides were washed, counterstained with Mayer’s haema-
toxylin and mounted. Negative control (substitution of the
primary antibody with Tris–buffered saline) and positive
control slides were included.
2.4. Interpretation of Shh immunostaining
Sections were evaluated independently without knowl-
edge of the clinicopathological characteristics of patients.
The expression pattern was  determined independently by
3 investigators (DG, WG,  and AA). Cytoplasmic staining of
tumour cells was  evaluated. Observer’s bias was  avoided by
repeating the evaluation of protein expression at 2 differ-
ent time points and without knowledge of patients’ clinical
data. Both staining intensity and extent (percentage) were
noted. The percentage was calculated by counting the per-
centage of positive tumour cells within the total number
of tumour cells in sections. The percentage was expressed
as; (1) when 0–10% of malignant cells were positive, (2)
when 11–50% of malignant cells were positive, and (3)
when labelling in more than 50% of malignant cells. The
staining intensity was  reported as; (0) negative; (1) weak;
(2) moderate; and (3) high. For statistical purpose, a com-
bination was  done between intensity and percentage and
was  given a numerical 6-scale score. Results were ﬁnally
dichotomised as low expression when score was 1–3 and
high expression when score was 4–6.
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Table  2
Categories of Shh immunoexpression in primary tumours and nodal
metastases.
Primary
tumour
(n = 155)
Nodal
metastasis
(n = 37)
p value
Low expression 38 (24.5%) 4 (10.8%) 0.941b
High expression 117 (75.5%) 33 (89.2%)
p  value 0.020a 0.004a
a One sample non-parametric chi-square test.
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Table 3
Relation of Shh immunoexpression to clinicopathological parameters.
p value
Age 0.096b
Sex 0.676b
Grade 0.004a
Tumour location 0.350a
Tumour size 0.618b
Depth of invasion (pT) 0.301a
Nodal metastasis 0.157a
Distant metastasis 0.617b
Lymphovascular invasion 0.850b
Margin status 0.610b
Survival 0.104b
Disease relapse 0.692b
a Kruskal–Wallis test.
b Mann–Whitney test.
Table 4
Regression analysis Shh immunoexpression.
Variable Exp(ˇ) 95% CI for exp(ˇ) p value
Nodal metastasis 0.545 0.270–1.102 0.091
Distant metastasis 1.335 0.546–3.262 0.526
Surgical resection margins 0.682 0.087–5.373 0.716b Mann–Whitney test.
.5. Statistical analysis
Differences between two groups of patients on one vari-
ble were tested by using Mann–Whitney test. To test
ssociation procedure in three groups of patients on one
ndependent variable the Kruskal–Wallis test was  used.
ilcoxon signed rank test was used to test differences
etween two related groups of paired variables Non-
arametric chi-square was used to test variance along one
ariable. Binary logistic regression analysis was used to
redict lymph noel metastasis, distant metastasis, surgical
esection margins involvement, lymphovascular invasion,
nd disease relapse in relation immunoexpression of
hh. Estimated odds ratio {exponential (B)}, 95% conﬁ-
ence interval (CI) for exp(B), and signiﬁcance denoted
or each analysis. The Kaplan–Meier procedure was  used
o calculate the disease-free survival probabilities and
he Log Rank test was used to compare the difference
etween survivals. Time was calculated from the date
f diagnosis to the appearance of disease relapse (or
ate last seen disease-free). Statistical procedures were
erformed using SPSS® Release 16.0. Statistical signif-
cance was determined at p value of ≤0.05 and was
-sided.
. Results
.1. Shh immunoexpression
The expression of Shh was deﬁned as cytoplasmic
taining with a stippled or granular pattern. In well dif-
erentiated carcinomas pattern of Shh expression is seen in
ithin the brush border of tumour cells (Fig. 1A). In moder-
tely differentiated carcinoma, more glandular structures
re involved and Shh is observed in the cytoplasm of malig-
ant cells (Fig. 1B). In poorly differentiated carcinoma and
odal metastasis, the inﬁltrating tumour cells show less
umber of cytoplasmic Shh immunostaining (Fig. 1C and
). In primary CRC there was a higher incidence of cases
ith high Shh immunoexpression than low immunoex-
ression (p = 0.02). In lymph node metastasis, high Shh
mmunoexpression was higher than low Shh immuno-
xpression (p = 0.004). However, there was no difference
etween Shh immunoexpression in primary carcinomas
nd lymph node metastasis (p = 0.941). Details are shown
able 2.Lymphovascular invasion 0.805 0.241–2.686 0.725
Disease relapse 0.652 0.340–1.250 0.198
3.2. Relationship between Shh immunoexpression and
clinicopathological parameters
There is a statistically signiﬁcant association between
Shh immunoexpression in primary CRC and low tumour
grade (p = 0.004). There was no statically signiﬁcant differ-
ence in Shh immunoexpression as regards age, sex, grade,
tumour location, depth of invasion (pT), nodal metasta-
sis, distant metastasis, lymphovascular invasion, margin
status, disease relapse, or status at end point. Results are
shown in Table 3.
Binary logistic regression analysis showed that Shh
immunoexpression was not an independent predictor
of positive margin status, lymphovascular invasion, dis-
ease relapse, or nodal and distant metastasis (Table 4).
Kaplan–Meier survival analyses showed that Shh immu-
noexpression in CRC had no signiﬁcant association
with favourable disease-free survival (log-rank = 0.079,
p = 0.778) (Fig. 2).
4. Discussion
Concomitant and sequential molecular multistep
genetic damages are required for CRC carcinogenesis to
occur starting by aberrant crypt proliferation or hyper-
plasia, adenomas to CRC, and ﬁnally metastatic carcinoma
[10]. The Hh signalling pathway plays an important role
during embryogenesis as well as adult life. It is involved
in regulation of proliferation, angiogenesis, matrix remod-
elling, stem cell renewal and the differentiation in several
tissues including the gastrointestinal tract [11,12]. Dys-
regulation of the Hh pathway is involved in tumour
development. Mutations of several components of Hh
pathway were found in patients with many types of
cancers including CRC [13,14]. Hh pathway involvement in
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 Diamin
aining o
taining oFig. 1. Shh immunostaining labelling in CRC by using anti-Shh antibody.
(A)  A well differentiated CRC showing extensive brush border immunost
CRC.  Staining is similar to well differentiated CRC (200×). (C, D) Immunos
is  less extensive in well and moderately differentiated CRC (200×).
tumorigenesis may  be related to the molecular pathways
of cancer stem cell [15].
The current study investigated the immunoexpression
of Shh in a subset of primary CRC and nodal metastasis. Shh
is overexpressed in both primary CRC and nodal metasta-
sis. The results from our study support the previous studies
regarding the involvement of the Shh pathway in colorec-
tal carcinogenesis and metastasis [1,6,15–18]. The Hh is
known to have an essential role in cellular proliferation,
and cell survival in many tissues [19,20]. Shh has been
shown to be localised to areas of increased cellular prolifer-
ation in human hyperplastic polyps and that staining was
more intense in areas of increased dysplasia in colorectal
adenomas and adenocarcinomas [4,21]. Accordingly, the
Hh signalling pathway may  have a possible role tumour
progression [22,23].
In the present study, no correlation was found between
Shh immunoexpression and most clinicopathological
features. In one study, there were similar ﬁndings [24].obenzidine was used as a chromogen and haematoxylin as counterstain.
f Shh (200×). (B) Immunostaining of Shh in a moderately differentiated
f Shh in a poorly differentiated CRC and lymph node metastasis. Staining
In other studies, there were some different results. Shh
overexpression correlated to early stage CRC [2,5]. Others
found association of Shh with nodal metastasis, disease
free survival and overall survival [2], and liver metastasis
[6]. The conﬂicting results may  be related to sample
size, and methodical issues. Given the paucity of studies
featuring the prognostic signiﬁcance of Shh in CRC, the
results from the current study and previous reports need
more validation.
In the present study, the high Shh immunoexpres-
sion was  signiﬁcantly associated with low grade CRC. In
this regard, there were conﬂicting ﬁndings in previous
reports. While some reported association of Shh with
more undifferentiated CRC [5]. Alinger et al., had shown
reduction in Shh expression in CRC than in benign lesions
and normal tissues. Also they reported that well differen-
tiated tumours shown more intense Shh expression than
high grade carcinomas [1]. Others found that there was
no association between Shh and tumour differentiation
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cig. 2. Disease-free survival curve (Kaplan–Meier) according to Shh im
log-rank = 0.079, p = 0.778).
2,24]. During embryogenesis, the Hh signalling pathway
s essential for organ patterning, cell differentiation and
ell proliferation [22]. The Hh signalling pathway is critical
o normal mammalian gastrointestinal development and
s involved in differentiation in normal colonic tissue
1,6,19,25–27]. Shh expression in the gastrointestinal tract
s limited to the region of stem cells. Accordingly Shh is
elated to gastrointestinal epithelial cell differentiation
5]. The ﬁndings of the current study as well as previous
eports support that Shh overexpression in CRC is related
o differentiation more than invasion and aggressiveness.
his may  result in speculation about the using the Hh
ignalling activation to be a therapeutic approach in CRC.
The limitation of the present study includes including
issing some follow-up data, short survival time in a num-
er of patients. Also, the lack of tissues from normal and
ysplastic colonic mucosa is another limitation.
. Conclusion
Shh is overexpressed in well differentiated CRC. How-
ver, Shh is not associated with other clinicopathological
nd prognostic factors. Loss of Shh may  be associated with
roliferation and loss of differentiation in CRC. Further
olecular studies are required to address the potential
mportance of Shh signalling in CRC including testing Shh
nhibitors and activators as potential therapeutic targets in
RC.
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